Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in August 2021 at the end of the 12-year period of market exclusivity.
This medicine is now known as plerixafor.
On 20 October 2004, orphan designation (EU/3/04/227) was granted by the European Commission to Orphix Consulting GmbH, Germany, for 1, 1'-[1,4-phenylenebis (methylene)]-bis-1,4,8,11- tetraazacyclotetradecane for treatment to mobilize progenitor cells prior to stem cell transplantation. The sponsorship was transferred to Genzyme Europe BV, the Netherlands, in June 2007.
l, 1'-[1,4-phenylenebis (methylene)]-bis-1,4,8,11- tetraazacyclotetradecane has been authorised in the EU as Mozobil since 31 July 2009.
The sponsor’s address was updated in December 2018.
1, 1'-[1,4-Phenylenebis (methylene)]-bis-1,4,8,11-tetraazacyclotetradecane (plerixafor)
Treatment to mobilize progenitor cells prior to stem cell transplantation
|Orphan designation status||
|EU designation number||
|Date of designation||
Documents related to this orphan designation evaluation
EU/3/04/227: Public summary of positive opinion for orphan designation of l, 1'-[1,4-phenylenebis (methylene)]-bis-1,4,8,11- tetraazacyclotetradecane for treatment to mobilize progenitor cells prior to stem cell tran... (PDF/305.31 KB)
First published: 18/08/2008
Last updated: 10/08/2021
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: